GO:0016521 pituitary adenylate cyclase activating polypeptide activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016521 describes the molecular function of pituitary adenylate cyclase activating polypeptide (PACAP), a hypothalamic peptide that binds receptors to exert pleiotropic effects including neurotransmitter release control, vasodilation, bronchodilation, intestinal motility activation, insulin and histamine secretion, immune modulation, and stimulation of cell proliferation and differentiation.
• PACAP signaling is centrally implicated in migraine pathophysiology, with both PACAP and CGRP contributing shared and independent mechanisms.
• PACAP exerts protective effects in stroke and dementia models, making it a candidate neuroprotective peptide.
• PACAP receptor antagonists such as PA-915 show rapid and long-lasting antidepressant-like effects in chronic stress mouse models.
• PACAP stimulates secretion in the adrenal medulla through defined cellular mechanisms.
• PACAP is present in articular cartilage and has emerging roles in joint biology.
Description
Pituitary adenylate cyclase activating polypeptide (PACAP) is a peptide produced in the hypothalamus that binds to receptors to exert pleiotropic effects including control of neurotransmitter release, vasodilation, bronchodilation, activation of intestinal motility, increase in insulin and histamine secretion, immune modulation, and stimulation of cell proliferation and differentiation. The Gene Ontology molecular function term GO:0016521 captures this activity. PACAP has attracted intense research interest because of its diverse physiological roles and its involvement in neurological and metabolic disorders [1, 4]. The peptide's structure-activity relationships have been a focus of neuroprotective peptide research. In migraine, PACAP is a key signaling molecule alongside CGRP, with shared and independent roles in pathophysiology. Targeting PACAP with monoclonal antibodies has been explored for migraine prevention. PACAP also has protective effects in stroke and dementia, suggesting therapeutic potential in neurodegenerative conditions. Recent work has identified PACAP receptor antagonists with antidepressant-like effects in chronic stress models. Additionally, PACAP regulates secretion in the adrenal medulla and is present in articular cartilage, indicating roles beyond the nervous system. Understanding GO:0016521 therefore requires integrating molecular, cellular, and disease-level knowledge.
pituitary adenylate cyclase activating polypeptide activity At A Glance
| GO ID | GO:0016521 |
|---|---|
| GO term | pituitary adenylate cyclase activating polypeptide activity |
| Ontology | molecular_function |
| Synonym | pituitary adenylyl cyclase activating polypeptide activity |
| Major function | Peptide hormone activity mediating neurotransmitter release, vasodilation, bronchodilation, intestinal motility, insulin and histamine secretion, immune modulation, and cell proliferation/differentiation |
| Source | Hypothalamus |
| Receptor binding | Binds to PACAP receptors to exert pleiotropic effects |
| Physiological systems | Nervous, cardiovascular, respiratory, gastrointestinal, endocrine, immune |
What Is GO:0016521?
GO:0016521, pituitary adenylate cyclase activating polypeptide activity, is a molecular function term defined as the action characteristic of pituitary adenylate cyclase activating polypeptide, a peptide produced in the hypothalamus that binds to receptors to exert pleiotropic effects including control of neurotransmitter release, vasodilation, bronchodilation, activation of intestinal motility, increase in insulin and histamine secretion, immune modulation, and stimulation of cell proliferation and differentiation. In essence, it describes the biological activity of the PACAP peptide itself as a signaling molecule.
Why Is pituitary adenylate cyclase activating polypeptide activity Important in Cell Biology?
GO:0016521 is important because PACAP is a multifunctional peptide involved in critical physiological processes and multiple human diseases. Its roles in neurotransmitter release, vasodilation, and immune modulation make it a key regulator of homeostasis [1, 4]. PACAP is implicated in migraine pathophysiology, with shared and independent roles alongside CGRP, and monoclonal antibodies targeting PACAP are being developed for migraine prevention. PACAP also shows protective effects in stroke and dementia, highlighting its neuroprotective potential. The peptide's structure-activity relationships are critical for designing therapeutic analogs. Furthermore, PACAP receptor antagonists have demonstrated antidepressant-like effects, suggesting a role in mood disorders. PACAP stimulates secretion in the adrenal medulla and is present in articular cartilage, indicating broader tissue roles. Thus, understanding GO:0016521 is essential for both basic biology and therapeutic development.
• PACAP is a key mediator of neurotransmitter release and neuroprotection.
• PACAP signaling is involved in migraine pathophysiology, with both shared and independent roles with CGRP.
• Monoclonal antibodies targeting PACAP are being explored for migraine prevention.
• PACAP has protective effects in stroke and dementia models.
• PACAP receptor antagonists show antidepressant-like effects in chronic stress models.
• PACAP stimulates secretion in the adrenal medulla.
• PACAP is present in articular cartilage, suggesting roles in joint biology.
• PACAP regulates vasodilation, bronchodilation, and intestinal motility.
• PACAP modulates insulin and histamine secretion and immune function.
• PACAP stimulates cell proliferation and differentiation.
Molecular Mechanism of pituitary adenylate cyclase activating polypeptide activity
Peptide Synthesis and Processing
In simple terms: PACAP is made in the hypothalamus as a larger precursor and then cut into its active form.
PACAP is produced in the hypothalamus and undergoes proteolytic processing to generate the active peptide. The structure-activity relationships of PACAP have been extensively studied, revealing key residues required for receptor binding and activation. The peptide exists in two forms, PACAP-38 and PACAP-27, both derived from the same precursor. These forms exhibit distinct tissue distributions and potencies, contributing to the pleiotropic effects described in GO:0016521.
Receptor Binding and Activation
In simple terms: PACAP binds to specific receptors on target cells, triggering signals inside the cell.
PACAP binds to PACAP receptors (PAC1, VPAC1, VPAC2) on target cells, leading to activation of adenylyl cyclase and increased cAMP production. This signaling cascade mediates the diverse effects of PACAP, including neurotransmitter release, vasodilation, and secretion [1, 4]. The binding specificity and affinity of PACAP analogs have been characterized to understand structure-activity relationships. In migraine, PACAP and CGRP share some signaling pathways but also have independent roles.
Downstream Signaling and Cellular Responses
In simple terms: Once activated, the receptor triggers a cascade that changes cell behavior.
Activation of PACAP receptors leads to downstream signaling events including cAMP accumulation, protein kinase A activation, and calcium mobilization. These pathways mediate the pleiotropic effects of PACAP, such as stimulation of insulin and histamine secretion, immune modulation, and cell proliferation and differentiation [1, 4]. In the adrenal medulla, PACAP stimulates secretion through specific cellular mechanisms involving calcium and other signaling molecules. PACAP also regulates neurotransmitter release and vasodilation, contributing to its role in migraine.
Regulation and Termination of Signaling
In simple terms: The signal is turned off by degrading PACAP or desensitizing receptors.
PACAP signaling is regulated by receptor desensitization, internalization, and peptide degradation. These mechanisms ensure that the pleiotropic effects are tightly controlled. Dysregulation of PACAP signaling has been implicated in migraine, where PACAP levels and receptor activity are altered. Targeting PACAP with monoclonal antibodies or receptor antagonists can modulate these pathways, as shown in migraine prevention and antidepressant-like effects [3, 6].
Key Genes Involved in GO:0016521 pituitary adenylate cyclase activating polypeptide activity
The following genes and proteins are central to pituitary adenylate cyclase activating polypeptide activity (GO:0016521) and its signaling pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADCYAP1 | Encodes PACAP peptide | Knockout models to study PACAP functions in neuroprotection and migraine [1, 8] |
| ADCYAP1R1 | Encodes PAC1 receptor | Point mutations to dissect receptor signaling in migraine and stress [3, 8] |
| VIPR1 | Encodes VPAC1 receptor | Knockout to study PACAP effects on vasodilation and secretion |
| VIPR2 | Encodes VPAC2 receptor | Overexpression to analyze cAMP signaling in immune modulation |
| CALCA | Encodes CGRP | Knock-in reporters to compare PACAP and CGRP pathways in migraine |
| CGRP receptor components | Mediate CGRP signaling | Knockout to study shared roles with PACAP in migraine |
| ADCYAP1R1 variants | Alter receptor function | Point mutation models for migraine susceptibility |
| PACAP antibodies | Neutralize PACAP | Monoclonal antibody development for migraine prevention |
| PA-915 | PACAP receptor antagonist | Antidepressant-like effects in chronic stress models |
| PACAP-38 | Major PACAP isoform | Structure-activity studies for neuroprotection |
| PACAP-27 | Minor PACAP isoform | Receptor binding studies |
| Adrenal medulla secretory proteins | Mediate PACAP-stimulated secretion | Knockout models to study secretion mechanisms |
| Articular cartilage proteins | PACAP effects in cartilage | Overexpression to study joint biology |
| Hypothalamic transcription factors | Regulate ADCYAP1 expression | Knock-in reporters to study PACAP production |
| cAMP signaling effectors | Downstream of PACAP receptors | Point mutations to dissect signaling [1, 4] |
| Immune cell receptors | Mediate immune modulation by PACAP | Knockout to study immune effects |
How Is pituitary adenylate cyclase activating polypeptide activity Regulated?
PACAP activity is regulated at multiple levels, including transcriptional control of ADCYAP1 in the hypothalamus, post-translational processing of the precursor peptide, and receptor desensitization. The peptide's effects are also modulated by degradation enzymes and binding proteins. In migraine, PACAP signaling is influenced by CGRP pathways, with shared and independent regulatory mechanisms. Receptor antagonists such as PA-915 can block PACAP signaling, leading to antidepressant-like effects in chronic stress models. Monoclonal antibodies targeting PACAP are being developed to modulate its activity in migraine prevention.
pituitary adenylate cyclase activating polypeptide activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADCYAP1 | Migraine | Knockout mouse for PACAP |
| ADCYAP1R1 | Migraine, stress | Point mutation knock-in mouse [3, 8] |
| ADCYAP1 | Stroke, dementia | Overexpression mouse for neuroprotection |
| ADCYAP1 | Articular cartilage degeneration | Knockout mouse for cartilage studies |
| ADCYAP1R1 | Depression | Antagonist treatment in chronic stress models |
PACAP in Migraine
PACAP is a key signaling molecule in migraine pathophysiology, with both shared and independent roles alongside CGRP. Targeting PACAP with monoclonal antibodies has emerged as a promising strategy for migraine prevention. Clinical and preclinical studies have shown that PACAP infusion can trigger migraine-like headaches, and PACAP receptor antagonists are being explored as therapeutics [6, 8].
PACAP in Neurodegeneration and Stroke
PACAP exerts protective effects in stroke and dementia models, suggesting its potential as a neuroprotective agent. The peptide's ability to modulate neurotransmitter release, reduce inflammation, and promote cell survival underlies these effects [1, 4]. Structure-activity studies have identified PACAP analogs with enhanced neuroprotective properties.
PACAP in Mood Disorders
PACAP receptor antagonists such as PA-915 produce rapid and long-lasting antidepressant-like effects in chronic stress mouse models. This suggests that PACAP signaling is involved in stress responses and mood regulation, and that targeting PACAP receptors may offer a novel approach for depression treatment.
PACAP in Cartilage and Joint Biology
PACAP is present in articular cartilage, where it may regulate chondrocyte function and joint homeostasis. Current knowledge indicates that PACAP could play a role in cartilage maintenance and repair, making it a potential target for osteoarthritis research.
From pituitary adenylate cyclase activating polypeptide activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PACAP protect against stroke? | ADCYAP1 knockout mouse with stroke induction |
| What is the role of PACAP in migraine? | PACAP receptor antagonist in migraine models [6, 8] |
| Can PACAP receptor antagonism treat depression? | PA-915 in chronic stress mouse models |
| How does PACAP stimulate adrenal secretion? | Adrenal medulla cell culture with PACAP treatment |
| What is PACAP's role in cartilage? | Articular cartilage explants with PACAP overexpression |
| What are the structure-activity relationships of PACAP? | PACAP analogs in receptor binding assays |
How to Study the pituitary adenylate cyclase activating polypeptide activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | PACAP receptor affinity | Structure-activity studies |
| cAMP assay | Adenylyl cyclase activation | Receptor signaling [1, 4] |
| Immunohistochemistry | PACAP localization | Tissue distribution [1, 7] |
| Behavioral tests | Migraine-like behaviors | Migraine models [6, 8] |
| Stroke models | Neuroprotection | Stroke studies |
| Chronic stress models | Depression-like behaviors | Antidepressant effects |
| Secretion assays | Adrenal medulla secretion | Secretion mechanisms |
| Cartilage explants | Chondrocyte function | Joint biology |
Peptide and Receptor Binding Assays
Radioligand binding assays and surface plasmon resonance can measure PACAP binding affinity to its receptors. These methods are used to study structure-activity relationships of PACAP analogs.
cAMP Signaling Assays
cAMP accumulation assays are used to measure PACAP receptor activation. This is a key readout for PACAP activity in cells, as PACAP stimulates adenylyl cyclase [1, 4].
Immunohistochemistry and Imaging
Immunohistochemistry can localize PACAP in tissues such as the hypothalamus and articular cartilage. Imaging techniques can track PACAP release and receptor internalization [1, 7].
Behavioral and Disease Models
Animal models of migraine, stroke, and depression are used to study PACAP function. Behavioral tests and disease induction protocols assess the effects of PACAP or its antagonists [1, 3, 6, 8].
How CRISPR Can Be Used to Study GO:0016521 pituitary adenylate cyclase activating polypeptide activity
Knockout
CRISPR knockout of ADCYAP1 or its receptors (ADCYAP1R1, VIPR1, VIPR2) can be used to study loss-of-function phenotypes in neuroprotection, migraine, and secretion. For example, ADCYAP1 knockout mice have been used to study PACAP's protective effects in stroke.
Point Mutation
Point mutations in ADCYAP1R1 can be introduced to dissect receptor signaling domains. Such models are valuable for understanding PACAP receptor function in migraine and stress responses [3, 8].
Knock-in
Knock-in of reporter genes (e.g., GFP) into the ADCYAP1 locus allows visualization of PACAP expression in vivo. This is useful for studying PACAP production in the hypothalamus and other tissues.
Overexpression
Overexpression of PACAP or its receptors can be achieved via CRISPR knock-in of a strong promoter or transgenic approaches. Overexpression models are used to study PACAP's effects on cartilage and neuroprotection [1, 7].
How EDITGENE Supports pituitary adenylate cyclase activating polypeptide activity Research
Researchers studying pituitary adenylate cyclase activating polypeptide activity-related genes often need to determine whether a candidate gene is causally involved in PACAP signaling, disease pathology, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for pituitary adenylate cyclase activating polypeptide activity research.
Frequently Asked Questions About pituitary adenylate cyclase activating polypeptide activity
What is pituitary adenylate cyclase activating polypeptide activity?
It is the molecular function defined by GO:0016521, describing the action of PACAP, a hypothalamic peptide that binds receptors to exert pleiotropic effects including neurotransmitter release, vasodilation, and immune modulation.
What genes are involved in pituitary adenylate cyclase activating polypeptide activity?
Key genes include ADCYAP1 (encoding PACAP), ADCYAP1R1 (PAC1 receptor), VIPR1, VIPR2, and CALCA (CGRP) [1, 8].
How is PACAP involved in migraine?
PACAP is a key signaling molecule in migraine, with shared and independent roles alongside CGRP, and monoclonal antibodies targeting PACAP are being developed for prevention [6, 8].
What are the neuroprotective effects of PACAP?
PACAP shows protective effects in stroke and dementia models, likely through modulation of neurotransmitter release and cell survival.
Can PACAP receptor antagonists treat depression?
Yes, the PACAP receptor antagonist PA-915 has shown rapid and long-lasting antidepressant-like effects in chronic stress mouse models.
How does PACAP stimulate secretion in the adrenal medulla?
PACAP stimulates secretion through specific cellular mechanisms involving calcium signaling and other pathways.
What is the role of PACAP in articular cartilage?
PACAP is present in articular cartilage and may regulate chondrocyte function, suggesting a role in joint biology.
What are the structure-activity relationships of PACAP?
Studies have identified key residues and analogs that affect receptor binding and neuroprotective activity.
How can CRISPR be used to study PACAP?
CRISPR can create knockout, point mutation, knock-in, and overexpression models of PACAP and its receptors to study function and disease [1, 3, 8].
What methods are used to measure PACAP activity?
Common methods include cAMP assays, radioligand binding, immunohistochemistry, and behavioral tests in animal models [1, 4, 6].
Conclusion
GO:0016521 pituitary adenylate cyclase activating polypeptide activity represents a multifunctional peptide with critical roles in neurobiology, cardiovascular function, immune modulation, and disease. Its involvement in migraine, stroke, dementia, depression, and cartilage biology underscores its therapeutic potential [1, 3, 6, 7, 8]. Understanding the molecular mechanisms and structure-activity relationships of PACAP is essential for developing targeted therapies. CRISPR-based models and EDITGENE services can accelerate this research, enabling precise genetic manipulation and functional studies.
References
- 1. Nonaka N et al.. 2020. Pituitary adenylate cyclase-activating polypeptide: Protective effects in stroke and dementia.. Peptides 130:170332 PMID: 32445876
- 3. Shintani Y et al.. 2026. Rapid and long-lasting antidepressant-like effects of the pituitary adenylate cyclase-activating polypeptide receptor antagonist PA-915 in chronic stress mouse models.. Mol Psychiatry 31(2):1014-1026 PMID: 40908362
- 4. Bourgault S et al.. 2009. Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide.. Curr Med Chem 16(33):4462-80 PMID: 19835562
- 5. Bell NA et al.. 2024. Cellular mechanisms underlying pituitary adenylate cyclase activating polypeptide-stimulated secretion in the adrenal medulla.. Biochem Soc Trans 52(6):2373-2383 PMID: 39656194
- 6. Rustichelli C et al.. 2020. Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review.. Expert Opin Investig Drugs 29(11):1269-1275 PMID: 32877252
- 7. Lauretta G et al.. 2020. Current knowledge of pituitary adenylate cyclase activating polypeptide (PACAP) in articular cartilage.. Histol Histopathol 35(11):1251-1262 PMID: 32542641
- 8. Kuburas A et al.. 2023. Shared and independent roles of CGRP and PACAP in migraine pathophysiology.. J Headache Pain 24(1):34 PMID: 37009867
